Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours-Reference-Cited by-同舟云学术

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours

Published:2006-01 Issue:1 Volume:42 Page:50-54
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Sternberg C.N.,de Mulder P.,Schornagel J.H.,Theodore C.,Fossa S.D.,van Oosterom A.T.,Witjes J.A.,Spina M.,van Groeningen C.J.,Duclos B.,Roberts J.T.,de Balincourt C.,Collette L.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference14 articles.

1. Cancer incidence and mortality in Europe, 2004;Boyle;Ann Oncol,2005

2. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a Cooperative Group Study;Loehrer;J Clin Oncol,1992

3. A prospective randomized trial comparing CISCA to MVAC chemotherapy in advanced metastastic urothelial tumours;Logothetis;J Clin Oncol,1990

4. Preliminary results of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial tumours;Sternberg;J Urol,1985

5. M-VAC for advanced transitional cell carcinoma of the urothelium: efficacy, and patterns of response and relapse;Sternberg;Cancer,1989

Cited by 470 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Das metastasierte und fortgeschrittene Urothelkarzinom des oberen Harntraktes – eigene Entität oder doch kleine Schwester des Blasenkarzinoms?;Die Urologie;2024-09-02

2. Identification and validation of sialyltransferase ST3Gal5 in bladder cancer through bioinformatics and experimental analysis;International Immunopharmacology;2024-09

3. Machine learning-based autophagy-related prognostic signature for personalized risk stratification and therapeutic approaches in bladder cancer;International Immunopharmacology;2024-09

4. Patient Preferences for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma: An Application of Multidimensional Thresholding;The Patient - Patient-Centered Outcomes Research;2024-08-28

5. Reevaluating the role of platinum-based chemotherapy in the evolving treatment landscape for patients with advanced urothelial carcinoma;The Oncologist;2024-08-21